Literature DB >> 2577281

Myocardial, coronary, and peripheral effects of xamoterol (ICI 118,587) in open-chest pigs.

N Galiè1, M Metalli, R Zannoli, G Binetti, A Branzi, B Magnani.   

Abstract

The hemodynamic and coronary effects of increasing doses of xamoterol, a beta-adrenoceptor partial agonist, were assessed in an anesthetized pig preparation in which cardiovascular reflexes were abolished and sympathetic tone was modified by infusion of noradrenaline (NA). Xamoterol, in basal conditions, increased heart rate (HR) from 104 +/- 12 to 120 +/- 13 beats/min (p less than .001); systolic, diastolic, and mean blood pressure, respectively, from 77 +/- 8 to 103 +/- 17 mmHg (p less than .01), from 48 +/- 7 to 70 +/- 12 mmHg (p less than .01), and from 58 +/- 7 to 84 +/- 14 mmHg (p less than .01); left ventricular dP/dT max from 2098 +/- 564 to 4205 +/- 937 mmHg/sec (p less than .001); and systemic vascular resistance (SVR) from 1745 +/- 564 to 2270 +/- 739 dynes sec cm-5 (p less than .01). The increase in HR and dP/dT max brought about by xamoterol was about 37% and 56%, respectively, of the maximum increase produced by NA. At the highest level of sympathetic tone, xamoterol reduced HR from 148 +/- 11 to 122 +/- 11 beats/min (p less than .001) and no significant change was observed in dP/dT max. The increase in blood pressure and SVR induced by xamoterol was maintained at each level of sympathetic tone. On the contrary, SVR did not change after NA, as expected, since receptors were fully blocked. For a given inotropic effect, xamoterol and NA produced a similar increase in coronary blood flow and myocardial O2 consumption.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2577281     DOI: 10.1007/bf01881533

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  17 in total

1.  Circulatory, respiratory and metabolic responses to isopropylnoradrenaline in man.

Authors:  A F COBBOLD; J GINSBURG; A PATON
Journal:  J Physiol       Date:  1960-06       Impact factor: 5.182

2.  Indications for the existence of two types of cardiac beta-adrenergic receptors.

Authors:  A C Dreyer; J Offermeier
Journal:  Pharmacol Res Commun       Date:  1975-04

3.  Comparison of the beta 1 selective affinity of prenalterol and corwin demonstrated by radioligand binding.

Authors:  N Cook; A Richardson; D B Barnett
Journal:  Eur J Pharmacol       Date:  1984-03-02       Impact factor: 4.432

4.  Treatment of idiopathic orthostatic hypotension with xamoterol.

Authors:  H Yamashita; O Yahara; N Hasebe; Y Kawamura; A Obara; H Honda; T Kimura; S Onodera
Journal:  Lancet       Date:  1987-06-20       Impact factor: 79.321

5.  The effects of beta 1-adrenoceptor partial agonist ICI 118.587 on left ventricular function in patients with coronary heart disease.

Authors:  M J Ikäheimo; J T Takkunen
Journal:  Int J Cardiol       Date:  1984-03       Impact factor: 4.164

6.  The in vitro pharmacology of xamoterol (ICI 118,587).

Authors:  E Malta; M A Mian; C Raper
Journal:  Br J Pharmacol       Date:  1985-05       Impact factor: 8.739

7.  Effects of xamoterol (ICI 118,587) in asthmatic patients.

Authors:  C G Löfdahl; N Svedmyr
Journal:  Br J Clin Pharmacol       Date:  1984-10       Impact factor: 4.335

8.  Cardioselectivity, kinetics, hemodynamics, and metabolic effects of xamoterol.

Authors:  G Jennings; A Bobik; C Oddie; R Restall
Journal:  Clin Pharmacol Ther       Date:  1984-05       Impact factor: 6.875

9.  Haemodynamic effects of ICI 118,587 in cardiomyopathy.

Authors:  S Simonsen
Journal:  Br Heart J       Date:  1984-06

10.  Xamoterol, a new selective beta-1-adrenoceptor partial agonist, in the treatment of postural hypotension.

Authors:  J Mehlsen; J Trap-Jensen
Journal:  Acta Med Scand       Date:  1986
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.